EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing its prescription Avenova® lid and lash hygiene product for the domestic eye care market, reports financial results for the three and nine months ended September 30, 2016, and provides a business update.
“This is an exceptional time at NovaBay as we achieved yet another quarter of record Avenova sales, growing 176% over the third quarter of 2015 and up 20% from the second quarter of 2016, and putting us on an estimated annualized run rate of $12 million,” said Mark M. Sieczkarek, NovaBay’s President and CEO. “Importantly, 68% of Avenova sales came from the higher-margin prescription ophthalmology channel. This is a 25% increase in prescription sales from the second quarter as we continue to execute on our channel strategy.
“This is an exceptional time at NovaBay as we achieved yet another quarter of record Avenova sales, growing 176% over the third quarter of 2015 and up 20% from the second quarter of 2016, and putting us on an estimated annualized run rate of $12 million,” said Mark M. Sieczkarek, NovaBay’s President and CEO. “Importantly, 68% of Avenova sales came from the higher-margin prescription ophthalmology channel. This is a 25% increase in prescription sales from the second quarter as we continue to execute on our channel strategy.
